EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)

M. Babjuk (Chair), M. Burger (Vice-Chair), E. Compérat, P. Gontero, A.H. Mostafid, J. Palou, B.W.G. van Rhijn, M. Rouprêt, S.F. Shariat, R. Sylvester, R. Zigeuner

© European Association of Urology 2018
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>INTRODUCTION</td>
<td>5</td>
</tr>
<tr>
<td>1.1</td>
<td>Aim and scope</td>
<td>5</td>
</tr>
<tr>
<td>1.2</td>
<td>Panel composition</td>
<td>5</td>
</tr>
<tr>
<td>1.3</td>
<td>Available publications</td>
<td>5</td>
</tr>
<tr>
<td>1.4</td>
<td>Publication history and summary of changes</td>
<td>5</td>
</tr>
<tr>
<td>1.4.1</td>
<td>Publication history</td>
<td>5</td>
</tr>
<tr>
<td>1.4.2</td>
<td>Summary of changes</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>METHODS</td>
<td>6</td>
</tr>
<tr>
<td>2.1</td>
<td>Data Identification</td>
<td>6</td>
</tr>
<tr>
<td>2.2</td>
<td>Review</td>
<td>6</td>
</tr>
<tr>
<td>2.3</td>
<td>Future goals</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY</td>
<td>7</td>
</tr>
<tr>
<td>3.1</td>
<td>Epidemiology</td>
<td>7</td>
</tr>
<tr>
<td>3.2</td>
<td>Aetiology</td>
<td>7</td>
</tr>
<tr>
<td>3.3</td>
<td>Pathology</td>
<td>7</td>
</tr>
<tr>
<td>3.4</td>
<td>Summary of evidence for epidemiology, aetiology and pathology</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>STAGING AND CLASSIFICATION SYSTEMS</td>
<td>8</td>
</tr>
<tr>
<td>4.1</td>
<td>Definition of non-muscle-invasive bladder cancer</td>
<td>8</td>
</tr>
<tr>
<td>4.2</td>
<td>Tumour, Node, Metastasis Classification (TNM)</td>
<td>8</td>
</tr>
<tr>
<td>4.3</td>
<td>T1 subclassification</td>
<td>8</td>
</tr>
<tr>
<td>4.4</td>
<td>Histological grading of non-muscle-invasive bladder urothelial carcinomas</td>
<td>8</td>
</tr>
<tr>
<td>4.5</td>
<td>Carcinoma in situ and its classification</td>
<td>9</td>
</tr>
<tr>
<td>4.6</td>
<td>Inter- and intra-observer variability in staging and grading</td>
<td>10</td>
</tr>
<tr>
<td>4.7</td>
<td>Further pathology parameters</td>
<td>10</td>
</tr>
<tr>
<td>4.8</td>
<td>Summary of evidence and guidelines for bladder cancer classification</td>
<td>10</td>
</tr>
<tr>
<td>5</td>
<td>DIAGNOSIS</td>
<td>10</td>
</tr>
<tr>
<td>5.1</td>
<td>Patient history</td>
<td>10</td>
</tr>
<tr>
<td>5.2</td>
<td>Signs and symptoms</td>
<td>10</td>
</tr>
<tr>
<td>5.3</td>
<td>Physical examination</td>
<td>10</td>
</tr>
<tr>
<td>5.4</td>
<td>Imaging</td>
<td>10</td>
</tr>
<tr>
<td>5.4.1</td>
<td>Computed tomography urography and intravenous urography</td>
<td>10</td>
</tr>
<tr>
<td>5.4.2</td>
<td>Ultrasound (US)</td>
<td>11</td>
</tr>
<tr>
<td>5.5</td>
<td>Urinary cytology</td>
<td>11</td>
</tr>
<tr>
<td>5.6</td>
<td>Urinary molecular marker tests</td>
<td>11</td>
</tr>
<tr>
<td>5.7</td>
<td>Potential application of urinary cytology and markers</td>
<td>12</td>
</tr>
<tr>
<td>5.7.1</td>
<td>Screening of the population at risk of bladder cancer</td>
<td>12</td>
</tr>
<tr>
<td>5.7.2</td>
<td>Exploration of patients after haematuria or other symptoms suggestive of bladder cancer (primary detection)</td>
<td>12</td>
</tr>
<tr>
<td>5.7.3</td>
<td>Surveillance of non-muscle-invasive bladder cancer</td>
<td>12</td>
</tr>
<tr>
<td>5.7.3.1</td>
<td>Follow-up of high-risk non-muscle-invasive bladder cancer</td>
<td>12</td>
</tr>
<tr>
<td>5.7.3.2</td>
<td>Follow-up of low/intermediate-risk non-muscle-invasive bladder cancer</td>
<td>12</td>
</tr>
<tr>
<td>5.8</td>
<td>Cystoscopy</td>
<td>12</td>
</tr>
<tr>
<td>5.9</td>
<td>Summary of evidence and guidelines for the primary assessment of non-muscle-invasive bladder cancer</td>
<td>13</td>
</tr>
<tr>
<td>5.10</td>
<td>Transurethral resection of TaT1 bladder tumours</td>
<td>13</td>
</tr>
<tr>
<td>5.10.1</td>
<td>Strategy of the procedure</td>
<td>13</td>
</tr>
<tr>
<td>5.10.2</td>
<td>Surgical and technical aspects of tumour resection</td>
<td>13</td>
</tr>
<tr>
<td>5.10.2.1</td>
<td>Surgical strategy of resection (resection in fractions, en-bloc resection)</td>
<td>13</td>
</tr>
<tr>
<td>5.10.2.2</td>
<td>Evaluation of resection quality</td>
<td>14</td>
</tr>
<tr>
<td>5.10.2.3</td>
<td>Monopolar and bipolar resection</td>
<td>14</td>
</tr>
</tbody>
</table>
5.10.2.4 Office-based fulguration and laser vaporisation
5.10.2.5 Resection of small papillary bladder tumours at the time of transurethral resection of the prostate (TURP)
5.10.3 Bladder and prostatic urethral biopsies
5.11 New methods of tumour visualisation
5.11.1 Photodynamic diagnosis (fluorescence cystoscopy)
5.11.2 Narrow-band imaging
5.12 Second resection
5.13 Pathology report
5.14 Summary of evidence and guidelines for transurethral resection of the bladder, biopsies and pathology report

6. PREDICTING DISEASE RECURRENTCE AND PROGRESSION
6.1 TaT1 tumours
6.2 Carcinoma in situ
6.3 Patient stratification into risk groups
6.4 Subgroup of highest-risk tumours
6.5 Summary of evidence and guidelines for stratification of non-muscle-invasive bladder cancer

7. DISEASE MANAGEMENT
7.1 Counselling of smoking cessation
7.2 Adjuvant treatment
7.2.1 Intravesical chemotherapy
7.2.1.1 A single, immediate, post-operative intravesical instillation of chemotherapy
7.2.1.2 Additional adjuvant intravesical chemotherapy instillations
7.2.1.3 Options for improving efficacy of intravesical chemotherapy
7.2.1.3.1 Adjustment of pH, duration of instillation, and drug concentration
7.2.1.3.2 Device-assisted intravesical chemotherapy
7.2.1.4 Summary of evidence - intravesical chemotherapy
7.2.2 Intravesical bacillus Calmette-Guérin (BCG) immunotherapy
7.2.2.1 Efficacy of BCG
7.2.2.2 BCG strain
7.2.2.3 BCG toxicity
7.2.2.4 Optimal BCG schedule
7.2.2.5 Optimal dose of BCG
7.2.2.6 Indications for BCG
7.2.2.7 Summary of evidence - BCG treatment
7.2.3 Combination therapy
7.2.4 Specific aspects of treatment of Carcinoma in situ
7.2.4.1 Treatment strategy
7.2.4.2 Cohort studies on intravesical BCG or chemotherapy
7.2.4.3 Prospective randomised trials on intravesical BCG or chemotherapy
7.2.4.4 Treatment of CIS in prostatic urethra and upper urinary tract
7.2.4.5 Summary of evidence – treatment of carcinoma in situ
7.3 Treatment of failure of intravesical therapy
7.3.1 Failure of intravesical chemotherapy
7.3.2 Recurrence and failure after intravesical bacillus Calmette-Guérin (BCG) immunotherapy
7.3.3 Treatment of BCG failure and recurrences after BCG
7.3.4 Summary of evidence - treatment failure of intravesical therapy
7.4 Radical cystectomy for NMIBC
7.5 Guidelines for adjuvant therapy in TaT1 tumours and for therapy of carcinoma in situ
7.6 Treatment recommendations in TaT1 tumours and carcinoma in situ according to risk stratification
7.7 Treatment options for bacillus Calmette-Guérin (BCG) failure and recurrences after BCG
1. INTRODUCTION

1.1 Aim and scope
This overview represents the updated European Association of Urology (EAU) Guidelines for Non-muscle-invasive Bladder Cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations.

Separate EAU Guidelines documents are available addressing upper tract urothelial carcinoma (UTUC) [1], muscle-invasive and metastatic bladder cancer (MIBC) [2], and primary urethral carcinoma [3]. It must be emphasised that clinical guidelines present the best evidence available to the experts, but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

1.2 Panel composition
The EAU Guidelines Panel on NMIBC consists of an international multidisciplinary group of clinicians, including urologists, uro-oncologists, a pathologist and a statistician. Members of this Panel have been selected based on their expertise and to represent the professionals treating patients suspected of suffering from bladder cancer. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website Uroweb: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/.

1.3 Available publications
A quick reference document (Pocket guidelines) is available, both in print and as an app for iOS and Android devices. These are abridged versions which may require consultation together with the full text version. Several scientific publications are available, the latest publication dating to 2016 [4], as are a number of translations of all versions of the EAU NMIBC Guidelines. All documents are accessible through the EAU website Uroweb: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/.

1.4 Publication history and summary of changes
1.4.1 Publication history
The EAU Guidelines on Bladder Cancer were first published in 2000. This 2018 NMIBC Guidelines document presents a limited update of the 2017 publication.

1.4.2 Summary of changes
Additional data has been included in sections:
- 4.4 4.4 - Histological grading of non-muscle-invasive bladder urothelial carcinomas
- 5.11.1 - Photodynamic diagnosis (fluorescence cystoscopy);
- 5.12 - Second resection;
- 7.2.1.3.2 - Device-assisted intravesical chemotherapy.

New recommendations have been added to:
- Section 5.9 - Summary of evidence and guidelines for the primary assessment of non-muscle-invasive bladder cancer

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>In men, use flexible cystoscope, if available.</td>
<td>Strong</td>
</tr>
<tr>
<td>Describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities during cystoscopy. Use a bladder diagram (Figure 5.1).</td>
<td>Strong</td>
</tr>
<tr>
<td>Use the Paris system for cytology reporting.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

- Section 5.14 - Summary of evidence and guidelines for transurethral resection of the bladder, biopsies and pathology report

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use methods to improve tumour visualization (FC, NBI) during TURB, if available.</td>
<td>Weak</td>
</tr>
</tbody>
</table>
2. METHODS

2.1 Data Identification

For the 2018 NMIBC Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature.

A broad and comprehensive scoping exercise covering all areas of the NMIBC Guidelines was performed. Excluded from the search were basic research studies, case series, reports and editorial comments. Only articles published in the English language, addressing adults, were included. The search was restricted to articles published between April 22\textsuperscript{nd} 2016 and May 24\textsuperscript{th} 2017. Databases covered by the search included Pubmed, Ovid, EMBASE and the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. After deduplication, a total of 2,631 unique records were identified, retrieved and screened for relevance.

A total of 35 new papers were added to the NMIBC 2018 Guidelines publication. A detailed search strategy is available online: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/?type=appendices-publications.

For Chapters 3-6 (Epidemiology, Aetiology and Pathology, Staging and Classification systems, Diagnosis, Predicting disease recurrence and progression) references used in this text are assessed according to their level of evidence (LE) based on the 2009 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence [5]. For the Disease Management and Follow-up chapters (Chapters 7 and 8) a system modified from the 2009 CEBM levels of evidence is being used [5].

For the 2018 edition of the EAU Guidelines the Guidelines Office have transitioned to a modified GRADE methodology across all 20 guidelines [6, 7]. For each recommendation within the guidelines there is an accompanying online strength rating form which addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation;
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words ‘strong’ or ‘weak’ [6, 7]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences. The strength rating forms will be available online.

Additional information can be found in the general Methodology section of this print, and online at the EAU website: http://www.uroweb.org/guideline/.

A list of associations endorsing the EAU Guidelines can also be viewed online at the above address.

2.2 Review

Publications of systematic reviews were peer reviewed prior to publication [8]. Chapter 7, Disease Management was peer reviewed prior to publication in 2016. All other chapters of the MIBC Guidelines were peer-reviewed in 2015.

2.3 Future goals

The results of ongoing reviews will be included in the 2019 update of the NMIBC Guidelines. These reviews are performed using standard Cochrane systematic review methodology; http://www.cochranelibrary.com/about/about-cochrane-systematic-reviews.html.

Ongoing projects:

- Individual Patient Data Prognostic Study on WHO 1973 & 2004 Grade and EORTC 2006 risk score in primary TaT1 Bladder Cancer;
- Systematic Review on lymphovascular invasion (LVI) and histology variants.
3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY

3.1 Epidemiology

Bladder cancer (BC) is the seventh most commonly diagnosed cancer in the male population worldwide, while it drops to eleventh when both genders are considered [9]. The worldwide age-standardised incidence rate (per 100,000 person/years) is 9.0 for men and 2.2 for women [9]. In the European Union the age-standardised incidence rate is 19.1 for men and 4.0 for women [9]. In Europe, the highest age-standardised incidence rate has been reported in Belgium (31 in men and 6.2 in women) and the lowest in Finland (18.1 in men and 4.3 in women) [9].

Worldwide, the BC age-standardised mortality rate (per 100,000 person/years) was 3.2 for men vs. 0.9 for women in 2012 [9]. Bladder cancer incidence and mortality rates vary across countries due to differences in risk factors, detection and diagnostic practices, and availability of treatments. The variations are, however, partly caused by the different methodologies used and the quality of data collection [10]. The incidence and mortality of BC has decreased in some registries, possibly reflecting the decreased impact of causative agents [11].

Approximately 75% of patients with BC present with a disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1); in younger patients (< 40) this percentage is even higher [12]. Patients with TaT1 and CIS have a high prevalence due to long-term survival in many cases and lower risk of cancer-specific mortality compared to T2-4 tumours [9, 10].

3.2 Aetiology

Tobacco smoking is the most important risk factor for BC, accounting for approximately 50% of cases [10, 11, 13, 14] (LE: 3). Tobacco smoke contains aromatic amines and polycyclic aromatic hydrocarbons, which are renally excreted.

Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons is the second most important risk factor for BC, accounting for about 10% of all cases. This type of occupational exposure occurs mainly in industrial plants, which process paint, dye, metal and petroleum products [10, 11, 15, 16]. In developed industrial settings, these risks have been reduced by work-safety guidelines, therefore, chemical workers no longer have a higher incidence of BC compared to the general population [10, 15, 16].

While family history seems to have little impact [17] and, to date, no overt significance of any genetic variation for BC has been shown, genetic predisposition has an influence on the incidence of BC via its impact on susceptibility to other risk factors [10, 18-22].

Although the impact of drinking habits is uncertain, the chlorination of drinking water and subsequent levels of trihalomethanes are potentially carcinogenic, also exposure to arsenic in drinking water increases risk [10, 23] (LE: 3). The association between personal hair dye use and risk remains uncertain; an increased risk has been suggested in users of permanent hair dyes with a slow NAT2 acetylation phenotype [10]. Dietary habits seem to have little impact [24-27].

Exposure to ionizing radiation is connected with increased risk; weak association was also suggested for cyclophosphamide and pioglitazone [10, 23, 28] (LE: 3). Schistosomiasis, a chronic endemic cystitis based on recurrent infection with a parasitic trematode, is also a cause of BC [10] (LE: 3).

3.3 Pathology

The information presented in this text is limited to urothelial carcinoma, unless otherwise specified.

3.4 Summary of evidence for epidemiology, aetiology and pathology

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worldwide, bladder cancer is the eleventh most commonly diagnosed cancer.</td>
<td>2a</td>
</tr>
<tr>
<td>Several risk factors connected with the risk of bladder cancer diagnosis have been identified.</td>
<td>3</td>
</tr>
</tbody>
</table>
4.  STAGING AND CLASSIFICATION SYSTEMS

4.1  Definition of non-muscle-invasive bladder cancer

Papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system [29]. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis). These tumours can be treated by transurethral resection of the bladder (TURB), eventually in combination with intravesical instillations and are therefore grouped under the heading of NMIBC for therapeutic purposes. However, molecular biology techniques and clinical experience have demonstrated the highly malignant potential of CIS and T1 lesions as compared to Ta lesions. The terms “NMIBC” and “superficial BC” are therefore suboptimal descriptions.

4.2  Tumour, Node, Metastasis Classification (TNM)

The 2009 TNM classification approved by the Union International Contre le Cancer (UICC) was updated in 2016 (8th Edn.), but with no changes in relation to bladder tumours (Table 4.1) [29].

Table 4.1: 2017 TNM classification of urinary bladder cancer

<table>
<thead>
<tr>
<th>T - Primary tumour</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
</tr>
<tr>
<td>T0</td>
</tr>
<tr>
<td>Ta</td>
</tr>
<tr>
<td>Tis</td>
</tr>
<tr>
<td>T1</td>
</tr>
<tr>
<td>T2</td>
</tr>
<tr>
<td>T2a</td>
</tr>
<tr>
<td>T2b</td>
</tr>
<tr>
<td>T3</td>
</tr>
<tr>
<td>T3a</td>
</tr>
<tr>
<td>T3b</td>
</tr>
<tr>
<td>T4</td>
</tr>
<tr>
<td>T4a</td>
</tr>
<tr>
<td>T4b</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N - Regional lymph nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
</tr>
<tr>
<td>N0</td>
</tr>
<tr>
<td>N1</td>
</tr>
<tr>
<td>N2</td>
</tr>
<tr>
<td>N3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M - Distant metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
</tr>
<tr>
<td>M1a</td>
</tr>
<tr>
<td>M1b</td>
</tr>
</tbody>
</table>

4.3  T1 subclassification

The depth and extent of invasion into the lamina propria (T1 substaging) has been demonstrated to be of prognostic value in retrospective cohort studies [30, 31] (LE: 3). Its use is recommended by the most recent 2016 World Health Organization (WHO) classification [32]. The optimal system to substage T1 remains to be defined [32, 33].

4.4  Histological grading of non-muscle-invasive bladder urothelial carcinomas

In 2004, the WHO and the International Society of Urological Pathology published a new histological classification of urothelial carcinomas which provides a different patient stratification between individual categories compared to the older 1973 WHO classification [34, 35] (Tables 4.2 and 4.3, Figure 4.1). Recently an update of the 2004 WHO grading classification was published [32], but the following guidelines are still based on the 1973 and 2004 WHO classifications since most published data rely on these two classifications [8, 34, 35].
Table 4.2: WHO grading in 1973 and in 2004 [34, 35]

<table>
<thead>
<tr>
<th>1973 WHO grading</th>
<th>2004 WHO grading system (papillary lesions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1: well differentiated</td>
<td>Papillary urothelial neoplasm of low malignant potential (PUNLMP)</td>
</tr>
<tr>
<td>Grade 2: moderately differentiated</td>
<td>Low-grade (LG) papillary urothelial carcinoma</td>
</tr>
<tr>
<td>Grade 3: poorly differentiated</td>
<td>High-grade (HG) papillary urothelial carcinoma</td>
</tr>
</tbody>
</table>

A recent systematic review and meta-analysis did not show that the 2004/2016 classification outperforms the 1973 classification in prediction of recurrence and progression [8] (LE: 2a).

There is a significant shift of patients between the prognostic categories of both systems, for example an increase in the number of HG patients (WHO 2004/2016) due to inclusion of some G2 patients with their better prognosis compared to G3 category (WHO 1973) [8]. As the 2004 WHO system has not been fully incorporated into prognostic models yet, long term individual patient data in both classification systems are needed.

4.5 Carcinoma in situ and its classification

Carcinoma in situ (CIS) is a flat, high-grade, non-invasive urothelial carcinoma. It can be missed or misinterpreted as an inflammatory lesion during cystoscopy if not biopsied. Carcinoma in situ is often multifocal and can occur in the bladder, but also in the upper urinary tract (UUT), prostatic ducts, and prostatic urethra [37].

Classification of CIS according to clinical type [38]:
- Primary: isolated CIS with no previous or concurrent papillary tumours and no previous CIS;
- Secondary: CIS detected during follow-up of patients with a previous tumour that was not CIS;
- Concurrent: CIS in the presence of any other urothelial tumour in the bladder.

Table 4.3: WHO 2004 histological classification for flat lesions

- Urothelial proliferation of uncertain malignant potential (flat lesion without atypia or papillary aspects).
- Reactive atypia (flat lesion with atypia).
- Atypia of unknown significance.
- Urothelial dysplasia.
- Urothelial CIS is always high grade.
4.6 Inter- and intra-observer variability in staging and grading

There is significant variability among pathologists for the diagnosis of CIS, for which agreement is achieved in only 70-78% of cases [39] (LE: 2a). There is also inter-observer variability in the classification of stage T1 vs. Ta tumours and tumour grading in both the 1973 and 2004 classifications. The general conformity in staging and grading is between 50% and 60% [40-43] (LE: 2a). The published comparisons have not clearly confirmed that the WHO 2004 classification provides better reproducibility than the 1973 classification [8, 40, 43-45].

4.7 Further pathology parameters

According to a meta-analysis of retrospective trials, the presence of lymphovascular invasion (LVI) in TURB specimens is connected with an increased risk of pathological upstaging [46] (LE: 3). Lymphovascular invasion has been reported as an unfavourable prognostic factor in T1 tumours [46-48] (LE: 3). Some variants of urothelial carcinoma (micropapillary, plasmocytoid, sarcomatoid) have a worse prognosis than classical urothelial carcinoma [2, 49-56] (LE: 3).

Molecular markers, particularly FGFR3 mutation status, are promising but need further validation [57-61].

4.8 Summary of evidence and guidelines for bladder cancer classification

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The depth of invasion (staging) is classified according to the TNM classification.</td>
<td>2a</td>
</tr>
<tr>
<td>Papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis).</td>
<td>2a</td>
</tr>
<tr>
<td>T1 and CIS, as compared to Ta, have high malignant potential; the term non-muscle-invasive bladder cancer (NMIBC) is therefore a suboptimal description.</td>
<td>3</td>
</tr>
<tr>
<td>For histological classification of NMIBC, both the WHO 1973 and 2004 grading systems are used.</td>
<td>2a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use the 2017 TNM system for classification of the depth of tumour invasion (staging).</td>
<td>Strong</td>
</tr>
<tr>
<td>Use both the 1973 and 2004/2016 WHO grading systems for histological classification.</td>
<td>Strong</td>
</tr>
<tr>
<td>Do not use the term “superficial bladder cancer”.</td>
<td>Strong</td>
</tr>
<tr>
<td>Mention the tumour stage and grade whenever the terminology NMIBC is used in individual cases.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

5. DIAGNOSIS

5.1 Patient history

A comprehensive patient history is mandatory.

5.2 Signs and symptoms

Haematuria is the most common finding in NMIBC. Visible haematuria was found to be associated with higher stage disease compared to nonvisible haematuria at first presentation [62]. Carcinoma in situ might be suspected in patients with lower urinary tract symptoms, especially irritative voiding.

5.3 Physical examination

Physical examination does not reveal NMIBC. Ultrasound may be performed as an adjunct to physical examination as it has moderately high sensitivity to a wide range of abnormalities but cannot rule out all potential causes of haematuria [63].

5.4 Imaging

5.4.1 Computed tomography urography and intravenous urography

Computed tomography (CT) urography is used to detect papillary tumours in the urinary tract, indicated by filling defects or hydronephrosis.

Intravenous urography (IVU) is an alternative if CT is not available [64] (LE: 2b), but particularly in muscle-invasive tumours of the bladder and in UTUCs, CT urography gives more information than IVU (including status of lymph nodes and neighbouring organs).
The necessity to perform a baseline CT urography or IVU once a bladder tumour has been detected is questionable due to the low incidence of significant findings obtained [65-67] (LE: 2b). The incidence of UTUCs is low (1.8%), but increases to 7.5% in tumours located in the trigone [66] (LE: 2b). The risk of UTUC during follow up increases in patients with multiple- and high-risk tumours [68] (LE: 2b).

5.4.2 Ultrasound (US)
Transabdominal US permits characterisation of renal masses, detection of hydronephrosis, and visualisation of intraluminal masses in the bladder [69] (LE: 3). Ultrasound is therefore a useful tool for detection of obstruction in patients with haematuria. However, it cannot exclude the presence of UTUC and cannot replace CT urography in bladder cancer detection.

The diagnosis of CIS cannot be made with imaging methods (CT urography, IVU or US) (LE: 4).

5.5 Urinary cytology
The examination of voided urine or bladder-washing specimens for exfoliated cancer cells has high sensitivity in G3 and high-grade tumours (84%), but low sensitivity in G1 and low-grade tumours (16%) [70]. The sensitivity in CIS detection is 28-100% [71] (LE: 1b). Cytology is useful, particularly as an adjunct to cystoscopy, if G3/CIS malignancy is present. Positive voided urinary cytology can indicate an urothelial tumour anywhere in the urinary tract; negative cytology, however, does not exclude the presence of a tumour.

Cytological interpretation is user-dependent [72]. Evaluation can be hampered by low cellular yield, urinary tract infections, stones, or intravesical instillations, however, in experienced hands specificity exceeds 90% [72] (LE: 2b).

A standardised reporting system redefining urinary cytology diagnostic categories was published in 2016 by the Paris Working Group [73]:
- Adequacy of urine specimens (Adequacy).
- Negative for high-grade urothelial carcinoma (Negative).
- Atypical urothelial cells (AUC).
- Suspicious for high-grade urothelial carcinoma (Suspicious).
- High-grade urothelial carcinoma (HGUC).
- Low-grade urothelial neoplasia (LGUN).

Urine collection should respect the recommendation provided in Section 5.9. One cytospin slide from the sample is usually sufficient [74]. In patients with suspicious cytology repeat investigation is advised [75] (LE: 2b).

5.6 Urinary molecular marker tests
Driven by the low sensitivity of urine cytology, numerous urinary tests were developed [76-79]. None of these markers have been accepted for diagnosis or follow-up in routine practice or clinical guidelines. A list of some of the more established urine tests (US Food and Drug Administration [FDA] approved and those for which multi-institutional data and multi-laboratory data are available) is listed in Table 5.1.

The following conclusions can be drawn regarding the existing tests:
- Sensitivity is usually higher at the cost of lower specificity, compared to urine cytology [76, 78-82] (LE: 3).
- Benign conditions and previous bacillus Calmette-Guérin (BCG) instillations influence many urinary marker tests [76, 78, 79] (LE: 1b).
- Requirements for sensitivity and specificity of a urinary marker test largely depend on the clinical context of the patient (screening, primary detection, follow up [high risk, low/intermediate risk]) [78, 79] (LE: 3).
- The wide range in performance of the markers listed in Table 5.1. and low reproducibility may be explained by patient selection and complicated laboratory methods required [79, 80, 83-90].
- Positive results of Cytology, UroVysion (FISH), NMP-22, Ucyt+, FGFR3/TERT and microsatellite analysis in patients with negative cystoscopy and upper tract work-up, may identify patients more likely to experience recurrence [84, 86, 89-92] and possibly progression [84, 86, 89-93] (LE: 2b).
Table 5.1: Summary of more established urinary markers

<table>
<thead>
<tr>
<th>Markers (or test specifications)</th>
<th>Overall sensitivity (%)</th>
<th>Overall specificity (%)</th>
<th>Sensitivity for high-grade tumours (%)</th>
<th>Point-of-care test</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>UroVysion (FISH)*</td>
<td>30-86</td>
<td>63-95</td>
<td>66-70</td>
<td>No</td>
<td>2b</td>
</tr>
<tr>
<td>Microsatellite analysis</td>
<td>58-92</td>
<td>73-100</td>
<td>90-92</td>
<td>No</td>
<td>1b</td>
</tr>
<tr>
<td>Immunocyt/uCyt +*</td>
<td>52-100</td>
<td>63-79</td>
<td>62-92</td>
<td>No</td>
<td>2a</td>
</tr>
<tr>
<td>Nuclear matrix Protein 22*</td>
<td>47-100</td>
<td>55-98</td>
<td>75-92</td>
<td>Yes</td>
<td>2a</td>
</tr>
<tr>
<td>BTA stat*</td>
<td>29-83</td>
<td>56-86</td>
<td>62-91</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>BTA TRAK*</td>
<td>53-91</td>
<td>28-83</td>
<td>74-77</td>
<td>No</td>
<td>3</td>
</tr>
<tr>
<td>Cytokeratins</td>
<td>12-88</td>
<td>73-95</td>
<td>33-100</td>
<td>No</td>
<td>3</td>
</tr>
</tbody>
</table>

BTA = bladder tumour antigen.

* FDA approved.

5.7 Potential application of urinary cytology and markers

The following objectives of urinary cytology or molecular tests must be considered.

5.7.1 Screening of the population at risk of bladder cancer

The application of haematuria dipstick, FGFR3, NMP22 or UroVysion in BC screening in high-risk populations has been reported [94, 95]. The low incidence of BC in the general population and the short lead-time impair feasibility and cost-effectiveness [92, 95]. Routine screening for BC is not recommended [92, 94, 95].

5.7.2 Exploration of patients after haematuria or other symptoms suggestive of bladder cancer (primary detection)

It is generally accepted that none of the currently available tests can replace cystoscopy. However, urinary cytology or biomarkers can be used as an adjunct to cystoscopy to detect invisible tumours, particularly CIS. In this setting, sensitivity for high-grade tumours and specificity are particularly important. Urinary cytology is highly specific, but urinary markers lack such high specificity and are not recommended for primary detection.

5.7.3 Surveillance of non-muscle-invasive bladder cancer

Research has been carried out into the usefulness of urinary cytology vs. markers in the follow up of NMIBC [83, 84, 96].

5.7.3.1 Follow-up of high-risk non-muscle-invasive bladder cancer

High-risk tumours should be detected early in follow up, and the percentage of tumours missed should be as low as possible. Therefore, the best surveillance strategy for these patients will continue to include frequent cystoscopy and cytology.

5.7.3.2 Follow-up of low/intermediate-risk non-muscle-invasive bladder cancer

To reduce the number of cystoscopy procedures, urinary markers should be able to detect recurrence before the tumours are large and numerous. The limitation of urinary cytology is its low sensitivity for low-grade recurrences. Several urinary markers are better, but still do not detect half of the low-grade tumours identified by cystoscopy [78, 84] (LE: 1b).

According to current knowledge, no urinary marker can replace cystoscopy during follow up or lower cystoscopy frequency in a routine fashion. One prospective randomised study found that knowledge of positive test results (microsatellite analysis) can improve the quality of follow-up cystoscopy [97] (LE: 1b), supporting the adjunctive role of a non-invasive urine test performed before follow-up cystoscopy [97].

5.8 Cystoscopy

The diagnosis of papillary BC ultimately depends on cystoscopic examination of the bladder and histological evaluation of sampled tissue by either cold-cup biopsy or resection. Carcinoma in situ is diagnosed by a combination of cystoscopy, urine cytology, and histological evaluation of multiple bladder biopsies [98].

Cystoscopy is initially performed as an outpatient procedure. A flexible instrument with topical intra-urethral anaesthetic lubricant instillation results in better compliance compared to a rigid instrument, especially in men [99, 100] (LE: 1b).
5.9 Summary of evidence and guidelines for the primary assessment of non-muscle-invasive bladder cancer

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The diagnosis of bladder cancer depends on cystoscopy examination.</td>
<td>1</td>
</tr>
<tr>
<td>Urinary cytology has high sensitivity in high-grade tumours including carcinoma in situ.</td>
<td>2b</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Take a patient history, focusing on urinary tract symptoms and haematuria.</td>
<td>Strong</td>
</tr>
<tr>
<td>Renal and bladder ultrasound and/or computed tomography-intravenous urography (CT-IVU) may be used during the initial work-up in patients with haematuria.</td>
<td>Weak</td>
</tr>
<tr>
<td>Once a bladder tumour has been detected, perform a computed tomography urography in selected cases (e.g., tumours located in the trigone, multiple- or high-risk tumours).</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform cystoscopy in patients with symptoms suggestive of bladder cancer or during surveillance. It cannot be replaced by cytology or by any other non-invasive test.</td>
<td>Strong</td>
</tr>
<tr>
<td>In men, use a flexible cystoscope, if available.</td>
<td>Strong</td>
</tr>
<tr>
<td>Describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities during cystoscopy. Use a bladder diagram (Figure 5.1).</td>
<td>Strong</td>
</tr>
<tr>
<td>Use voided urine cytology as an adjunct to cystoscopy to detect high-grade tumour.</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform cytology on fresh urine or urine with adequate fixation. Morning urine is not suitable because of the frequent presence of cytolysis.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use the Paris system for cytology reporting.</td>
<td>Strong</td>
</tr>
<tr>
<td>Repeat urine cytology in patients with initial cytology results suspicious for high-grade urothelial carcinoma.</td>
<td>Weak</td>
</tr>
</tbody>
</table>

5.10 Transurethral resection of TaT1 bladder tumours

5.10.1 Strategy of the procedure

The goal of TURB in TaT1 BC is to make the correct diagnosis and completely remove all visible lesions. It is a crucial procedure in the diagnosis and treatment of BC. TURB should be performed systematically in individual steps [101] (see Section 5.14).

5.10.2 Surgical and technical aspects of tumour resection

5.10.2.1 Surgical strategy of resection (resection in fractions, en-bloc resection)

A complete resection is essential to achieve a good prognosis [102]. A complete resection can be achieved by either fractioned or en-bloc resection [101].
• Resection in fractions (separate resection of the exophytic part of the tumour, the underlying bladder wall and the edges of the resection area) provides good information about the vertical and horizontal extent of the tumour [103] (LE: 2b).

• *En-bloc* resection using monopolar or bipolar current, Thulium-YAG or Holmium-YAG laser is feasible in selected exophytic tumours. It provides high quality resected specimens with the presence of detrusor muscle in 96-100% of cases [101, 104-107] (LE: 1b).

The technique selected is dependent on the size and location of the tumour and experience of the surgeon.

5.10.2.2 Evaluation of resection quality
It has been confirmed that the absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease, early recurrence and tumour understaging [108] (LE: 1b). The presence of detrusor muscle in the specimen is considered as the surrogate criterion of the resection quality and is required (except of TaG1/LG tumours). It has been shown that surgical experience can improve TURB results, which supports the role of teaching programmes [109].

5.10.2.3 Monopolar and bipolar resection
Compared to monopolar resection, bipolar resection has been introduced to reduce the risk of complications (e.g., bladder perforation due to obturator nerve stimulation) and to produce better specimens for the pathologist. Currently, the results remain controversial [110-113].

5.10.2.4 Office-based fulguration and laser vaporisation
In patients with a history of small, TaLG/G1 tumours, fulguration of small papillary recurrences on an outpatient basis can reduce the therapeutic burden and is a treatment option [114] (LE: 3). There are no prospective comparative studies assessing the oncological outcomes.

Potassium titanyl-phosphate (KTP) laser vaporisation is associated with a low risk of complications. Its oncologic outcomes need to be confirmed in a larger patient population [115].

5.10.2.5 Resection of small papillary bladder tumours at the time of transurethral resection of the prostate (TURP)
Only limited, retrospective, data exist on the outcome of incidentally detected papillary bladder tumour during cystoscopy as the initial step of TURP. Provided these tumours are papillary by aspect, rather small and not extensively multifocal, it seems feasible to resect these tumours and continue with the resection of the prostate. However, no exact risk-assessment can be provided [116, 117].

5.10.3 Bladder and prostatic urethral biopsies
Carcinoma in situ can present as a velvet-like, reddish, area indistinguishable from inflammation, or it may not be visible at all. For this reason, the strategy of taking biopsies from abnormal urothelium and biopsies from normal-looking mucosa (random/mapping biopsies) is recommended (see Section 5.14). The indication for random biopsies reflects the very low likelihood of detecting CIS, especially in low-risk tumours (< 2%) [118] (LE: 1b). The risk increases in patients with high-risk tumours and with positive cytology [119].

If equipment is available, photodynamic diagnosis (PDD) is a useful tool to target the biopsy (see Section 5.11.1). Involvement of the prostatic urethra and ducts in men with NMIBC has been reported. Palou et al. [120] showed that in 128 men with T1G3 BC, the incidence of CIS in the prostatic urethra was 11.7% (LE: 2b). The risk of prostatic urethra or duct involvement is higher if the tumour is located at the trigone or bladder neck, in the presence of bladder CIS and multiple tumours [121] (LE: 3b). Based on this observation, a biopsy from the prostatic urethra is necessary in some cases (see recommendation in Section 5.14) [120, 122].

5.11 New methods of tumour visualisation
As a standard procedure, cystoscopy and TURB are performed using white light. However, the use of white light can lead to missing lesions that are present but not visible, which is why new technologies are being developed.

5.11.1 Photodynamic diagnosis (fluorescence cystoscopy)
Photodynamic diagnosis (PDD) is performed using violet light after intravesical instillation of 5-aminolaevulinic acid (ALA) or hexaminolaevulinic acid (HAL). It has been confirmed that fluorescence-guided biopsy and resection are more sensitive than conventional procedures for the detection of malignant tumours, particularly for CIS [123, 124] (LE: 1a). In a systematic review and meta-analysis, PDD had higher sensitivity than white light endoscopy in the pooled estimates for analyses at both the patient-level (92% vs.71%) and biopsy-level (93% vs. 65%) [124]. A prospective randomised trial did not confirm a higher detection rate in patients with known positive cytology before TURB [125].
Photodynamic diagnosis had lower specificity than white-light endoscopy (63% vs. 81%) [124]. False-positivity can be induced by inflammation or recent TURB and during the first three months after BCG instillation [126, 127] (LE: 1a).

The beneficial effect of ALA or HAL FC on recurrence rate in patients with TURB was evaluated by more prospective, randomised trials. The meta-analysis of 14 RCTs evaluating ALA or HAL FC published in 2017 demonstrated reduced recurrence rates in patients with FC guided TURB [128] (LE: 1a).

The value of fluorescence-guided TURB for the improvement of outcome in relation to progression rate, survival and clinical management remains to be demonstrated.

5.11.2 Narrow-band imaging

In narrow-band imaging (NBI), the contrast between normal urothelium and hyper-vascular cancer tissue is enhanced. Cohort studies have demonstrated improved cancer detection by NBI flexible cystoscopy and NBI-guided biopsies and resection [129-131] (LE: 3b). The reduction of recurrence rate if NBI is used during TURB has been confirmed after three and twelve months for low-risk tumours (pTaLG, < 30 mm, no CIS) [132] (LE: 1b).

5.12 Second resection

The significant risk of residual tumour after initial TURB of TaT1 lesions has been demonstrated [102] (LE: 1b). Persistent disease after resection of T1 tumours has been observed in 33-55% of patients, after resection of TaG3 tumour in 41.4% [133-136]. Moreover, the tumour is often understaged in the initial resection. The likelihood that muscle-invasive disease is detected by second resection of initially T1 tumour ranges from 1.3-25%, and increases to 45% if there was no muscle in the initial resection [125, 137-140]. This risk increased to 50% in some radical cystectomy (RC) series, although these studies only enrolled selected patients [141-143] (LE: 2a). Treatment of a TaT1 high-grade tumour and a T2 tumour is completely different; correct staging is therefore important. It has been demonstrated that a second TURB can increase recurrence-free survival [133, 134] (LE: 2a), improve outcomes after BCG treatment [144] (LE: 3) and provide prognostic information [139, 141, 145] (LE: 3).

In a retrospective evaluation of a large multi-institutional cohort of 2,451 patients with BCG-treated T1G3/HG tumours (second resection was performed in 935 patients), the second resection improved recurrence-free survival (RFS), progression-free survival (PFS) and overall survival (OS) only in patients without muscle in the specimen from initial resection [146] (LE: 3).

According to a meta-analysis of published trials, the prevalence rate for residual tumours and upstaging to invasive disease remains high even in the subgroup of T1 tumours with muscle in the specimen. In the total population of 3,556 patients with T1 tumours, disease persistence was detected in 61% and tumour understaging in 15% of cases, whereas in the subgroup of 1,565 T1 tumours with muscle presence, the risk was 58% and 11%. The analysis, however, showed significant heterogeneity between studies [147].

Retrospective evaluation showed that a second resection performed 14-42 days after initial resection provides longer RFS and PFS compared to second resection performed after 43-90 days [148] (LE: 3). Based on these arguments, a second TURB is recommended in selected cases two-six weeks after initial resection (for recommendations on patient selection, see Section 5.14).

The results of the second resection (residual tumours and understaging) reflect the quality of the initial TURB. As the goal is to improve the quality of the initial TURB, the results of the second resection should be recorded.

5.13 Pathology report

Pathological investigation of the specimen(s) obtained by TURB and biopsies is an essential step in the diagnosis and treatment decision-making process for BC [149]. Close co-operation between urologists and pathologists is required. A high quality of resected and submitted tissue and clinical information is essential for correct pathological assessment. The presence of sufficient muscle is necessary for the correct assignment of the T category. To obtain all relevant information, the specimen collection, handling and evaluation should respect the recommendations provided below (see Section 5.14) [150]. In difficult cases, an additional review by an experienced genitourinary pathologist should be considered.
5.14 Summary of evidence and guidelines for transurethral resection of the bladder, biopsies and pathology report

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transurethral resection of the bladder (TURB) followed by pathology investigation of the obtained specimen(s) is an essential step in the treatment of NMIBC.</td>
<td>1</td>
</tr>
<tr>
<td>The absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease and tumour understaging.</td>
<td>2b</td>
</tr>
<tr>
<td>In patients with a history of small, TaLG/G1 tumours, fulguration of small papillary recurrences on an outpatient basis is feasible and safe.</td>
<td>3</td>
</tr>
<tr>
<td>A second TURB can detect residual tumours and tumour understaging, increase recurrence-free survival, improve outcomes after BCG treatment and provide prognostic information.</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients suspected of having bladder cancer, perform a TURB followed by pathology investigation of the obtained specimen(s) as a diagnostic procedure and initial treatment step.</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform TURB systematically in individual steps:</td>
<td>Strong</td>
</tr>
<tr>
<td>• bimanual palpation under anaesthesia;</td>
<td></td>
</tr>
<tr>
<td>• insertion of the resectoscope, under visual control with inspection of the whole urethra;</td>
<td></td>
</tr>
<tr>
<td>• inspection of the whole urothelial lining of the bladder;</td>
<td></td>
</tr>
<tr>
<td>• biopsy from the prostatic urethra (if indicated);</td>
<td></td>
</tr>
<tr>
<td>• cold-cup bladder biopsies (if indicated);</td>
<td></td>
</tr>
<tr>
<td>• resection of the tumour;</td>
<td></td>
</tr>
<tr>
<td>• recording of findings in the surgery report/record;</td>
<td></td>
</tr>
<tr>
<td>• precise description of the specimen for pathology evaluation.</td>
<td></td>
</tr>
<tr>
<td>Perform en-bloc resection or resection in fractions (exophytic part of the tumour, the underlying bladder wall and the edges of the resection area). The presence of detrusor muscle in the specimen is required in all cases except for TaG1/LG tumours.</td>
<td>Strong</td>
</tr>
<tr>
<td>Avoid cauterisation as much as possible during TURB to avoid tissue deterioration.</td>
<td>Strong</td>
</tr>
<tr>
<td>Take biopsies from abnormal-looking urothelium. Biopsies from normal-looking mucosa (trigone, bladder dome, and right, left, anterior and posterior bladder wall) are recommended when cytology is positive or when high-risk exophytic tumour is expected (non-papillary appearance). If equipment is available, perform fluorescence-guided (PDD) biopsies.</td>
<td>Strong</td>
</tr>
<tr>
<td>Take biopsy of the prostatic urethra in cases of bladder neck tumour, when bladder carcinoma in situ is present or suspected, when there is positive cytology without evidence of tumour in the bladder, or when abnormalities of the prostatic urethra are visible. If biopsy is not performed during the initial procedure, it should be completed at the time of the second resection.</td>
<td>Strong</td>
</tr>
<tr>
<td>Take the biopsy from abnormal areas in the prostatic urethra and from the precollicular area (between the 5 and 7 o’clock position) using a resection loop. In primary non-muscle-invasive tumours when stromal invasion is not suspected, cold-cup biopsy with forceps can be used.</td>
<td>Weak</td>
</tr>
<tr>
<td>Use methods to improve tumour visualization (FC, NBI) during TURB, if available.</td>
<td>Weak</td>
</tr>
<tr>
<td>Refer the specimens from different biopsies and resection fractions to the pathologist in separately labelled containers.</td>
<td>Weak</td>
</tr>
<tr>
<td>The TURB protocol must describe tumour appearance, all steps of the procedure, as well as the extent and completeness of resection.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients with positive cytology, but negative cystoscopy, exclude an upper tract urothelial carcinoma, CIS in the bladder (random biopsies or PDD-guided biopsies) and tumour in the prostatic urethra (prostatic urethra biopsy).</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform a second TURB in the following situations:</td>
<td>Strong</td>
</tr>
<tr>
<td>• after incomplete initial TURB, or in case of doubt about completeness of a TURB;</td>
<td></td>
</tr>
<tr>
<td>• if there is no muscle in the specimen after initial resection, with the exception of TaLG/G1 tumours and primary CIS;</td>
<td></td>
</tr>
<tr>
<td>• in T1 tumours.</td>
<td></td>
</tr>
</tbody>
</table>
If indicated, perform a second TURB within two-six weeks after initial resection. This second TURB should include resection of the primary tumour site.  

Weak

Register the pathology results of a second TURB as it reflects the quality of the initial resection.  

Weak

Inform the pathologist of prior treatments (intravesical therapy, radiotherapy, etc.).  

Strong

**Pathological report**

The pathological report should specify tumour location, tumour grade, depth of tumour invasion, presence of CIS, and whether the detrusor muscle is present in the specimen.  

Strong

The pathological report should specify the presence of lymphovascular invasion or unusual (variant) histology.  

Strong

6. **PREDICTING DISEASE RECURRENT AND PROGRESSION**

6.1 **TaT1 tumours**

Treatment should be based on a patient’s prognosis. In order to predict, separately, the short- and long-term risks of disease recurrence and progression in individual patients, the EORTC Genito-Urinary Cancer Group has developed a scoring system and risk tables [151]. The basis for these tables are individual patient data from 2,596 patients diagnosed with TaT1 tumours, who were randomised into seven EORTC trials. Patients with CIS alone were not included. Seventy-eight percent of patients received intravesical treatment, mostly chemotherapy. However, they did not undergo a second TURB or receive maintenance BCG.

The scoring system is based on the six most significant clinical and pathological factors which are shown in Table 6.1. It also illustrates the weights applied to various factors for calculating the total scores for recurrence and progression. Table 6.2 shows the total scores stratified, into four categories that reflect various probabilities of recurrence and progression at one and five years [151] (LE: 2a).

**Table 6.1: Weighting used to calculate disease recurrence and progression scores**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Recurrence</th>
<th>Progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2-7</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>≥ 8</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Tumour diameter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 3 cm</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>≥ 3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Prior recurrence rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>≤ 1 recurrence/year</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>&gt; 1 recurrence/year</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Category</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ta</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>T1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Concurrent CIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Yes</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>G2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>G3</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Total Score</td>
<td>0-17</td>
<td>0-23</td>
</tr>
</tbody>
</table>
The prognosis of intermediate-risk patients treated with chemotherapy has been calculated in a recently published paper. Patients with Ta G1/G2 tumours receiving chemotherapy were further stratified into three risk groups for recurrence, taking into account the history of recurrences, history of intravesical treatment, tumour grade, number of tumours and adjuvant chemotherapy [152].

A scoring model for BCG-treated patients that predicts the short- and long-term risks of recurrence and progression has been published by the Club Urológico Español de Tratamiento Oncológico (CUETO) (Spanish Urological Oncology Group). It is based on an analysis of 1,062 patients from four CUETO trials that compared different intravesical BCG treatments. Patients received twelve instillations over five-six months. No immediate post-operative instillation or second TURB was performed in these patients. The scoring system is based on the evaluation of seven prognostic factors:

- gender;
- age;
- prior recurrence status;
- number of tumours;
- T category;
- associated CIS;
- tumour grade.

Using these tables, the calculated risk of recurrence is lower than that obtained by the EORTC tables. For progression, probability is lower only in high-risk patients [153] (LE: 2a). The lower risks in the CUETO tables may be attributed to the use of BCG in this sample, which is a more effective instillation therapy. The CUETO risk calculator is available at: http://www.aeu.es/Cueto.html.

The prognostic value of the EORTC scoring system has been confirmed by data from the CUETO patients treated with BCG and by long-term follow up in an independent patient population [154, 155] (LE: 2a).

In 1,812 intermediate- and high-risk patients without CIS treated with one to three years of maintenance BCG, the EORTC found that the prior disease-recurrence rate and number of tumours were the most important prognostic factors for disease recurrence, stage and grade were the most important prognostic factors for disease progression and disease-specific survival, while age and grade were the most important prognostic factors for OS. T1G3 patients do poorly, with one- and five-year disease-progression rates of 11.4% and 19.8%, respectively. Using these data the new EORTC risk groups and nomograms for BCG treated patients were designed [156] (LE: 2a).

Further prognostic factors have been described in selected patient populations:

- In T1G3 tumours important prognostic factors were female sex, CIS in the prostatic urethra in men treated with an induction course of BCG, and age, tumour size and concurrent CIS in BCG-treated patients (62% with induction course only) [120, 157] (LE: 2b).

Notice must be given to patients with T1G3 tumours in bladder (pseudo) diverticulum because of the absence of muscle layer in the diverticular wall [158] (LE: 3).

### Table 6.2: Probability of recurrence and disease progression according to total score

<table>
<thead>
<tr>
<th>Recurrence score</th>
<th>Probability of recurrence at 1 year</th>
<th>Probability of recurrence at 5 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (95% CI)</td>
<td>% (95% CI)</td>
</tr>
<tr>
<td>0</td>
<td>15 (10-19)</td>
<td>31 (24-37)</td>
</tr>
<tr>
<td>1-4</td>
<td>24 (21-26)</td>
<td>46 (42-49)</td>
</tr>
<tr>
<td>5-9</td>
<td>38 (35-41)</td>
<td>62 (58-65)</td>
</tr>
<tr>
<td>10-17</td>
<td>61 (55-67)</td>
<td>78 (73-84)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Progression score</th>
<th>Probability of progression at 1 year</th>
<th>Probability of progression at 5 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (95% CI)</td>
<td>% (95% CI)</td>
</tr>
<tr>
<td>0</td>
<td>0.2 (0-0.7)</td>
<td>0.8 (0-1.7)</td>
</tr>
<tr>
<td>2-6</td>
<td>1 (0.4-1.6)</td>
<td>6 (5-8)</td>
</tr>
<tr>
<td>7-13</td>
<td>5 (4-7)</td>
<td>17 (14-20)</td>
</tr>
<tr>
<td>14-23</td>
<td>17 (10-24)</td>
<td>45 (35-55)</td>
</tr>
</tbody>
</table>

• In patients with high-risk disease, the tumour stage at the time of the second TURB is an unfavourable prognostic factor [141, 145] (LE: 3).
• In patients with T1G2 tumours treated with TURB, recurrence at three months was the most important predictor of progression [159] (LE: 2b).
• The prognostic value of pathological factors has been discussed elsewhere (see Section 4.6). More research is needed to determine the role of molecular markers in improving the predictive accuracy of currently available risk tables [154, 160].

6.2 Carcinoma in situ
Without any treatment, approximately 54% of patients with CIS progress to muscle-invasive disease [161] (LE: 3). Unfortunately, there are no reliable prognostic factors that can be used to predict the course of the disease. Publications are based on retrospective analyses of small series of patients and conclusions are not homogeneous. Some studies have reported a worse prognosis in concurrent CIS and T1 tumours compared to primary CIS [162, 163], extended CIS [164] and CIS in the prostatic urethra [120] (LE: 3).

The response to intravesical treatment with BCG or chemotherapy is an important prognostic factor for subsequent progression and death caused by BC [153-155, 159]. Approximately 10-20% of complete responders eventually progress to muscle-invasive disease, compared with 66% of non-responders [165, 166] (LE: 2a).

6.3 Patient stratification into risk groups
To facilitate treatment recommendations it is important to categorise patients into risk groups. Based on available prognostic factors and, in particular, data from the EORTC risk tables, the Guidelines Panel recommends stratification of patients into three risk groups. Table 6.3 provides a definition of these risk groups, which takes into account the EORTC risk tables' probabilities of recurrence and, especially, progression.

6.4 Subgroup of highest-risk tumours
Based on prognostic factors, it is possible to substratify high-risk group patients, and identify those that are at the highest risk of disease progression. Patients diagnosed with T1G3/HG tumours associated with concurrent bladder CIS, multiple- and/or large T1G3/HG tumours and/or recurrent T1G3/HG, T1G3/HG with CIS in the prostatic urethra, some forms of variant histology of urothelial carcinoma, and T1 tumours with LVI (Table 6.3) are at the highest risk of progression.

Table 6.3: Risk group stratification

<table>
<thead>
<tr>
<th>Risk group stratification</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-risk tumours</td>
<td>Primary, solitary, TaG1 (PUNLMP, LG*), &lt; 3 cm, no CIS</td>
</tr>
<tr>
<td>Intermediate-risk tumours</td>
<td>All tumours not defined in the two adjacent categories (between the category of low- and high risk).</td>
</tr>
<tr>
<td>High-risk tumours</td>
<td>Any of the following:</td>
</tr>
<tr>
<td></td>
<td>• T1 tumour</td>
</tr>
<tr>
<td></td>
<td>• G3 (HG**) tumour</td>
</tr>
<tr>
<td></td>
<td>• carcinoma in situ (CIS)</td>
</tr>
<tr>
<td></td>
<td>• Multiple, recurrent and large (&gt; 3 cm) TaG1G2 /LG tumours (all features must be present)*.</td>
</tr>
<tr>
<td>Subgroup of highest risk tumours:</td>
<td>T1G3/HG associated with concurrent bladder CIS, multiple- and/or large T1G3/HG and/or recurrent T1G3/HG, T1G3/HG with CIS in the prostatic urethra, some forms of variant histology of urothelial carcinoma, lymphovascular invasion.</td>
</tr>
</tbody>
</table>

Substratification of high-risk tumours for clinical purposes is addressed in Table 7.2.
*Low grade is a mixture of G1 and G2.
** High grade is a mixture of some G2 and all G3 (see Figure 4.1).
6.5 Summary of evidence and guidelines for stratification of non-muscle-invasive bladder cancer

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The EORTC scoring system and risk tables predict the short- and long-term risks of disease recurrence and progression in individual patients with non-muscle-invasive bladder cancer (NMIBC).</td>
<td>2a</td>
</tr>
<tr>
<td>Patients with Ta G1/G2 tumours receiving chemotherapy have been further stratified into three risk groups for recurrence, taking into account the history of recurrences, history of intravesical treatment, tumour grade, number of tumours and adjuvant chemotherapy.</td>
<td>2a-b</td>
</tr>
<tr>
<td>In patients treated with BCG, the CUETO scoring model predicts the short- and long-term risks of disease recurrence and progression.</td>
<td>2a</td>
</tr>
<tr>
<td>In patients receiving BCG maintenance; prior recurrence rate and number of tumours are the most important prognostic factors for disease recurrence.</td>
<td>2a</td>
</tr>
<tr>
<td>Stage and grade are the most important prognostic factors for disease progression and disease specific survival.</td>
<td>2a</td>
</tr>
<tr>
<td>Patient age and grade are the most important prognostic factors for overall survival.</td>
<td>2a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stratify patients into three risk groups according to Table 6.3.</td>
<td>Strong</td>
</tr>
<tr>
<td>Apply the EORTC risk tables and calculator for the prediction of the risk of tumour recurrence and progression in different intervals after transurethral resection of the bladder, in individual patients.</td>
<td>Strong</td>
</tr>
<tr>
<td>Use the CUETO risk tables and the new EORTC risk groups for the prediction of the risk of tumour recurrence and progression in individual patients treated with bacillus Calmette-Guérin.</td>
<td>Strong</td>
</tr>
</tbody>
</table>

7. DISEASE MANAGEMENT

7.1 Counselling of smoking cessation

It has been confirmed that smoking increases the risk of tumour recurrence and progression [167, 168] (LE: 3). While it is still controversial whether smoking cessation in BC will favourably influence the outcome of BC treatment, patients should be counselled to stop smoking due to the general risks connected with tobacco smoking [169-172] (LE: 3).

7.2 Adjuvant treatment

7.2.1 Intravesical chemotherapy

Although TURB by itself can eradicate a TaT1 tumour completely, these tumours commonly recur and can progress to MIBC. The high variability in the three-month recurrence rate indicates that the TURB was incomplete or provokes recurrences in a high percentage of patients [102]. It is therefore necessary to consider adjuvant therapy in all patients.

7.2.1.1 A single, immediate, post-operative intravesical instillation of chemotherapy

Immediate single instillation (SI) has been shown to act by destroying circulating tumour cells after TURB, and by an ablative effect (chemo resection) on residual tumour cells at the resection site and on small overlooked tumours [173-176] (LE: 3).

Four large meta-analyses comprising 1,476 to 3,103 patients have consistently shown that after TURB, SI significantly reduces the recurrence rate compared to TURB alone [177-180] (LE: 1a). In the most recent systematic review and individual patient data meta-analysis of 2,278 eligible patients [177], SI reduced the five-year recurrence rate by 14%, from 59% to 45%. The number to treat (NNT) to prevent one recurrence within five years was seven eligible patients. Only patients with a prior recurrence rate of less than or equal to one recurrence per year and those with an EORTC recurrence score \(< 5\) benefited from SI. In patients with an EORTC recurrence score \(\geq 5\) and/or patients with a prior recurrence rate of \(> 1\) recurrence per year, SI was not effective as a single adjuvant treatment. Mitomycin C (MMC), epirubicin, and pirarubicin have all shown a beneficial effect [177]. No randomised comparisons of individual drugs have been conducted [177-180] (LE: 1a).
Prevention of tumour cell implantation should be initiated within the first few hours after TURB. After that, tumour cells are firmly implanted and are covered by the extracellular matrix [173, 181, 182] (LE: 3). In all SI studies, the instillation was administered within 24 hours. To maximise the efficacy of SI, one should devise flexible practices that allow the instillation to be given as soon as possible after TURB, preferably within the first two hours in the recovery room or even in the operating theatre. As severe complications have been reported in patients with drug extravasation [183, 184] safety measures should be maintained (see Section 7.5).

7.2.1.2 Additional adjuvant intravesical chemotherapy instillations

The need for further adjuvant intravesical therapy depends on prognosis. In low-risk patients (Tables 6.1, 6.2 and 6.3), a SI reduces the risk of recurrence and is considered to be the standard and complete treatment [177, 178] (LE: 1a). For other patients, however, a SI remains an incomplete treatment because of the considerable likelihood of recurrence and/or progression (Tables 6.1, 6.2 and 6.3).

Efficacy data for the following comparisons were published:

Single installation only vs. SI + further repeat instillations
In one study [185], further chemotherapy instillations after SI improved recurrence-free survival in intermediate-risk patients (LE: 2a).

Repeat chemotherapy instillations vs. no adjuvant treatment
A large meta-analysis of 3,703 patients from eleven randomised trials showed a highly significant (44%) reduction in the odds of recurrence at one year in favour of chemotherapy over TURB alone [186]. This corresponds to an absolute difference of 13-14% in the number of patients with recurrence. Contrary to these findings, two meta-analyses have demonstrated that BCG therapy may reduce the risk of tumour progression [187, 188] (LE: 1a) (see Section 7.2.2.1). Moreover, BCG maintenance therapy appears to be significantly better in preventing recurrences than chemotherapy [189-191] (see Section 7.2.2.1) (LE: 1a). However, BCG causes significantly more side effects than chemotherapy [191] (LE: 1a).

Single instillation + further repeat instillations vs. later repeat instillations only
There is evidence from several studies in intermediate-risk patients that SI might have an impact on recurrence even when further adjuvant instillations are given [192-195]. A recent RCT including 2,243 NMIBC patients, which compared SI of MMC with an instillation of MMC delayed two weeks after TURBT (followed by further repeat instillations in both treatment arms), showed a significant reduction of 9% in the risk of recurrence at three years in favour of SI, from 36% to 27%. The effect was significant in the intermediate- and high-risk groups of patients receiving additional adjuvant MMC instillations [192] (LE: 2a). Unfortunately, the authors’ definition of risk groups differed significantly from those currently recommended. As a consequence, some patients did not receive adequate therapy and the study cannot reliably answer the question of whether SI improves the efficacy of further instillations [192].

The length and frequency of repeat chemotherapy instillations is still controversial. A SR of RCTs, comparing different schedules of intravesical chemotherapy instillations, concluded that the ideal duration and intensity of the schedule remains undefined because of conflicting data [195]. The available evidence does not support treatment longer than one year (LE: 3).

7.2.1.3 Options for improving efficacy of intravesical chemotherapy

7.2.1.3.1 Adjustment of pH, duration of instillation, and drug concentration
One RCT using MMC has demonstrated that adapting urinary pH, decreasing urinary excretion, and buffering the intravesical solution reduced the recurrence rate [196] (LE: 1b). Another trial reported that duration of a one hour instillation of MCC was more effective compared to a 30 minute instillation, but no efficacy comparisons are available for one- vs. two-hour durations of instillation [197] (LE: 3). Another RCT using epirubicin has documented that concentration is more important than treatment duration [198] (LE: 1b). In view of these data, instructions are provided (see Section 7.5).

7.2.1.3.2 Device-assisted intravesical chemotherapy

Microwave-induced hyperthermia
Promising data have been presented on enhancing the efficacy of MMC using microwave-induced hyperthermia in patients with high-risk tumours [199]. In one RCT comparing one year of BCG with one year MMC and microwave-induced hyperthermia in patients with intermediate- and high-risk bladder cancer, a reduced RFS at 24 months in the MMC group was demonstrated [200] (LE: 1b).
Hyperthermic intravesical chemotherapy
Different technologies which increase the temperature of instilled MMC are available, however, data about their efficacy are still lacking.

Electromotive drug administration (EMDA)
The efficacy of MMC using EMDA sequentially combined with BCG in patients with high-risk tumours has been demonstrated in one small RCT [201]. The definitive conclusion however, needs further confirmation.

7.2.1.4 Summary of evidence - intravesical chemotherapy

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients with non-muscle-invasive bladder cancer and a prior low recurrence rate (≤ one recurrence per year) and in those with an EORTC recurrence score &lt; 5, a single instillation (SI) significantly reduces the recurrence rate compared to transurethral resection of the bladder alone.</td>
<td>1a</td>
</tr>
<tr>
<td>Single instillation might have an impact on recurrence even when further adjuvant chemotherapy instillations are given.</td>
<td>3</td>
</tr>
<tr>
<td>Repeat chemotherapy instillations (with or without previous SI) improve recurrence-free survival in intermediate-risk patients.</td>
<td>2a</td>
</tr>
</tbody>
</table>

7.2.2 Intravesical bacillus Calmette-Guérin (BCG) immunotherapy

7.2.2.1 Efficacy of BCG

Five meta-analyses have confirmed that BCG after TURB is superior to TURB alone or TURB + chemotherapy for preventing the recurrence of NMIBC [189, 202-205] (LE: 1a). Three recent RCTs of intermediate- and high-risk tumours have compared BCG with epirubicin + interferon [206], MMC [207], or epirubicin alone [190] and have confirmed the superiority of BCG for prevention of tumour recurrence (LE: 1a). The effect is longlasting [190, 207] and was also observed in a separate analysis of patients with intermediate-risk tumours [190].

One meta-analysis [189] has evaluated the individual data from 2,820 patients enrolled in nine RCTs that have compared MMC vs. BCG. In the trials with BCG maintenance, there was a 32% reduction in the risk of recurrence for BCG compared to MMC, but a 28% increase in the risk of recurrence for patients treated with BCG in the trials without BCG maintenance.

Two meta-analyses have demonstrated that BCG therapy delays and potentially lowers the risk of tumour progression [187, 188] (LE: 1a). A meta-analysis carried out by the EORTC-Genito Urinary Cancers Group (GUCC) has evaluated data from 4,863 patients enrolled in 24 RCTs. Five different BCG strains were used, and in 20 of the trials, some form of BCG maintenance was used. Based on a median follow-up of 2.5 years, in 260 out of 2,658 patients (9.8%) treated with BCG, tumours progressed, compared to 304 out of 2,205 (13.8%) in the control groups (TURB alone, TURB + intravesical chemotherapy, or TURB + other immunotherapy). This shows a reduction of 27% in the odds of progression with BCG maintenance treatment. The size of the reduction was similar in patients with TaT1 papillary tumours and in those with CIS [188]. A recent RCT with long-term observation has demonstrated significantly fewer distant metastases and better overall- and disease-specific survival in patients treated with BCG compared to epirubicin [190] (LE: 1b). In contrast, a meta-analysis of individual patient data was not able to confirm any statistically significant difference between MMC and BCG for progression, survival and cause of death [189].

The conflicting results in the outcomes of these studies can be explained by different patient characteristics, duration of follow-up, methodology and statistical power. However, most studies showed a reduction in the risk of progression in high- and intermediate-risk tumours if BCG was applied including a maintenance schedule.

Two other meta-analyses have suggested a possible bias in favour of BCG arising from the inclusion of patients previously treated with intravesical chemotherapy [208]. In the most recent meta-analysis, however, BCG maintenance was more effective than MMC, both in patients previously treated and not previously treated with chemotherapy [189] (LE: 1a). It was demonstrated that BCG was less effective in patients > 70 years of age, but still more effective than epirubicin in a cohort of elderly patients [209] (LE: 1a).

7.2.2.2 BCG strain

The EORTC meta-analysis suggested no large differences in efficacy between various BCG strains [188]. Recently published smaller studies without maintenance demonstrated some differences between strains. This clearly needs further evaluation in prospective trials [210, 211] (LE: 2a).
7.2.2.3 **BCG toxicity**

Bacillus Calmette-Guérin intravesical treatment is associated with more side effects compared to intravesical chemotherapy [188] (LE: 1a). However, serious side effects are encountered in < 5% of patients and can be treated effectively in almost all cases [212] (LE: 1b). It has been shown that a maintenance schedule is not associated with an increased risk of side effects compared to an induction course [212]. Side effects requiring treatment stoppage were seen more often in the first year of therapy [213]. Elderly patients do not seem to experience more side effects leading to treatment discontinuation [214] (LE: 2a).

Major complications can appear after systemic absorption of the drug. Thus, contraindications of BCG intravesical instillation should be respected (see Section 7.5). The presence of leukocycturia, nonvisible haematuria or asymptomatic bacteriuria is not a contraindication for BCG application, and antibiotic prophylaxis is not necessary in these cases [215, 216] (LE: 3).

Bacillus Calmette-Guérin should be used with caution in immunocompromised patients; e.g. immunosuppression, human immunodeficiency virus [HIV] infection pose relative contraindications [217], although some small studies have shown similar efficacy and no increase in complications compared to non-immunocompromised patients. The role of prophylactic anti-tuberculosis medication in these patients remains unclear [218-220] (LE: 3). The management of side effects after BCG should reflect their type and grade according to the recommendations provided by the International Bladder Cancer Group (IBCG) and by a Spanish group [221, 222] (Table 7.1).

**Table 7.1: Management options for side effects associated with intravesical bacillus Calmette-Guérin (BCG) [222-225]**

<table>
<thead>
<tr>
<th>Management options for local side effects (modified from International Bladder Cancer Group)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptoms of cystitis</strong></td>
</tr>
<tr>
<td>Phenazopyridine, propantheline bromide, or non-steroidal anti-inflammatory drugs (NSAIDs)</td>
</tr>
<tr>
<td>If symptoms improve within a few days: continue instillations</td>
</tr>
<tr>
<td>If symptoms persist or worsen:</td>
</tr>
<tr>
<td>a. Postpone the instillation</td>
</tr>
<tr>
<td>b. Perform a urine culture</td>
</tr>
<tr>
<td>c. Start empirical antibiotic treatment</td>
</tr>
<tr>
<td>If symptoms persist even with antibiotic treatment:</td>
</tr>
<tr>
<td>a. With positive culture: adjust antibiotic treatment according to sensitivity</td>
</tr>
<tr>
<td>b. With negative culture: quinolones and potentially analgesic anti-inflammatory instillations once daily for 5 days (repeat cycle if necessary) [223].</td>
</tr>
<tr>
<td>If symptoms persist: anti-tuberculosis drugs + corticosteroids.</td>
</tr>
<tr>
<td>If no response to treatment and/or contracted bladder: radial cystectomy.</td>
</tr>
<tr>
<td><strong>Haematuria</strong></td>
</tr>
<tr>
<td>Perform urine culture to exclude haemorrhagic cystitis, if other symptoms present.</td>
</tr>
<tr>
<td>If haematuria persists, perform cystoscopy to evaluate presence of bladder tumour.</td>
</tr>
<tr>
<td><strong>Symptomatic granulomatous prostatitis</strong></td>
</tr>
<tr>
<td>Symptoms rarely present: perform urine culture.</td>
</tr>
<tr>
<td>Quinolones.</td>
</tr>
<tr>
<td>If quinolones are not effective: isoniazid (300 mg/day) and rifampicin (600 mg/day) for three months.</td>
</tr>
<tr>
<td>Cessation of intravesical therapy.</td>
</tr>
<tr>
<td><strong>Epididymo-orchitis</strong></td>
</tr>
<tr>
<td>Perform urine culture and administer quinolones.</td>
</tr>
<tr>
<td>Cessation of intravesical therapy.</td>
</tr>
<tr>
<td>Orchidectomy if abscess or no response to treatment.</td>
</tr>
<tr>
<td><strong>Management options for systemic side effects</strong></td>
</tr>
<tr>
<td><strong>General malaise, fever</strong></td>
</tr>
<tr>
<td>Generally resolve within 48 hours, with or without antipyretics.</td>
</tr>
<tr>
<td><strong>Arthralgia and/or arthritis</strong></td>
</tr>
<tr>
<td>Rare complication and considered autoimmune reaction.</td>
</tr>
<tr>
<td>Arthralgia: treatment with NSAIDs.</td>
</tr>
<tr>
<td>Arthritis: NSAIDs.</td>
</tr>
<tr>
<td>If no/partial response, proceed to corticosteroids, high-dose quinolones or antituberculosis drugs [225].</td>
</tr>
<tr>
<td><strong>Persistent high-grade fever (&gt; 38.5°C for &gt; 48 h)</strong></td>
</tr>
<tr>
<td>Permanent discontinuation of BCG instillations.</td>
</tr>
<tr>
<td>Immediate evaluation: urine culture, blood tests, chest X-ray.</td>
</tr>
<tr>
<td>Prompt treatment with more than two antimicrobial agents while diagnostic evaluation is conducted.</td>
</tr>
<tr>
<td>Consultation with an infectious diseases specialist.</td>
</tr>
</tbody>
</table>
BCG sepsis

Prevention: initiate BCG at least 2 weeks post-transurethral resection of the bladder (if no signs and symptoms of haematuria).

Cessation of BCG.

For severe infection:
- High-dose quinolones or isoniazid, rifampicin and ethambutol 1.2 g daily for 6 months.
- Early, high-dose corticosteroids as long as symptoms persist.
- Consider an empirical non-specific antibiotic to cover Gram-negative bacteria and/or Enterococcus.

Allergic reactions

Antihistamines and anti-inflammatory agents.

Consider high-dose quinolones or isoniazid and rifampicin for persistent symptoms.

Delay therapy until reactions resolve.

7.2.2.4 Optimal BCG schedule

Induction BCG instillations are given according to the empirical six-weekly schedule introduced by Morales [226]. For optimal efficacy, BCG must be given in a maintenance schedule [187-189, 205] (LE: 1a). Many different maintenance schedules have been used, ranging from a total of ten instillations given in eighteen weeks to 27 over three years [227]. The EORTC meta-analysis was unable to determine which BCG maintenance schedule was the most effective [188]. In their meta-analysis, Böhle et al. concluded that at least one year of maintenance BCG is required to obtain superiority of BCG over MMC for prevention of recurrence or progression [187] (LE: 1a).

The optimal number of induction instillations and the optimal frequency and duration of maintenance instillations is not fully known. Moreover, it can be different in each individual patient [228]. In a RCT of 1,355 patients, the EORTC has shown that when BCG is given at full dose, three years’ maintenance (three-weekly instillations 3, 6, 12, 18, 24, 30 and 36 months) reduces the recurrence rate compared to one year in high- but not in intermediate-risk patients. There were no differences in progression or OS. In the three-year arm, however, 36.1% of patients did not complete the three-year schedule [229] (LE: 1b). In a RCT of 397 patients CUETO suggested that in high-risk tumours, the maintenance schedule with only one instillation every three months for three years may be suboptimal [230] (LE: 1b).

7.2.2.5 Optimal dose of BCG

To reduce BCG toxicity, instillation of a reduced dose was proposed. However, it has been suggested that a full dose of BCG is more effective in multifocal tumours [231, 232] (LE: 1b). The CUETO study compared one-third dose to full-dose BCG and found no overall difference in efficacy. One-third of the standard dose of BCG might be the minimum effective dose for intermediate-risk tumours. A further reduction to one-sixth dose resulted in a decrease in efficacy with no decrease in toxicity [233] (LE: 1b).

The EORTC did not find any difference in toxicity between one-third and full-dose BCG, but one third dose BCG was associated with a higher recurrence rate, especially when it was given only for one year [213, 229] (LE: 1b). The routine use of one-third dose BCG is complicated by potential technical difficulties in preparing the reduced dose reliably, given uneven distribution of colony-forming-units in the dry product formulation.

7.2.2.6 Indications for BCG

Although BCG is very effective, there is consensus that not all patients with NMIBC should be treated with BCG due to the risk of toxicity. Ultimately, the choice of treatment depends upon the patient’s risk (Table 6.2). The recommendation for individual risk groups is provided in Section 7.5.

A statement by the Panel on BCG shortage can be accessed online: https://uroweb.org/guideline/non-muscleinvasive-bladder-cancer/?type=appendices-publications.

7.2.2.7 Summary of evidence - BCG treatment

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients with intermediate- and high-risk tumours, intravesical bacillus Calmette-Guérin (BCG) after TURB reduces the risk of tumour recurrence; it is more effective than TURB alone or TURB + intravesical chemotherapy.</td>
<td>1a</td>
</tr>
<tr>
<td>For optimal efficacy, BCG must be given in a maintenance schedule.</td>
<td>1a</td>
</tr>
<tr>
<td>Three-year maintenance is more effective than one year to prevent recurrence in patients with high-risk tumours, but not in patients with intermediate-risk tumours.</td>
<td>1a</td>
</tr>
</tbody>
</table>
7.2.3 Combination therapy

In one RCT, a combination of MMC and BCG was shown to be more effective in reducing recurrences but more toxic compared to BCG monotherapy (LE: 1b). Using similar BCG schedules in both groups, each BCG instillation in the combination group was preceded a day before by one MMC instillation [234]. In a Cochrane meta-analysis of 4 RCTs including NMIBC at high risk of recurrence and progression, a combination of BCG + IFN 2α did not show a clear difference in recurrence and progression over BCG alone. In one study, weekly MMC followed by monthly BCG alternating with IFN 2α showed a higher probability of recurrence compared to MMC followed by BCG alone [235]. Additionally, a recent RCT in a similar population of NMIBC comparing BCG monotherapy with a combination of epirubicin and interferon for up to two years showed the latter was significantly inferior to BCG monotherapy in preventing recurrence [236] (LE: 1b). In an RCT using MMC with EMDA, a combination of BCG and MMC with EMDA showed an improved recurrence-free interval and reduced progression rate compared to BCG monotherapy [201, 237] (LE: 2).

7.2.4 Specific aspects of treatment of Carcinoma in situ

7.2.4.1 Treatment strategy

The detection of concurrent CIS increases the risk of recurrence and progression of TaT1 tumours [151, 153], in this case further treatment according to the criteria summarised in Sections 7.2.1, 7.2.2, 7.3 and 7.4 is mandatory. Carcinoma in situ cannot be cured by an endoscopic procedure alone. Histological diagnosis of CIS must be followed by further treatment, either intravesical BCG instillations or RC (LE: 4). Tumour-specific survival rates after immediate RC for CIS are excellent, but as many as 40-50% of patients might be over treated [161] (LE: 3).

7.2.4.2 Cohort studies on intravesical BCG or chemotherapy

In retrospective evaluations of patients with CIS, a complete response rate of 48% was achieved with intravesical chemotherapy and 72-93% with BCG [161-164, 238] (LE: 2a). Up to 50% of complete responders might eventually show recurrence with a risk of invasion and/or extravesical recurrence [164, 227, 238, 239] (LE: 3).

7.2.4.3 Prospective randomised trials on intravesical BCG or chemotherapy

Unfortunately, there have been few randomised trials in patients with CIS only. A meta-analysis of clinical trials comparing intravesical BCG to intravesical chemotherapy in patients with CIS has shown a significantly increased response rate after BCG and a reduction of 59% in the odds of treatment failure with BCG [240] (LE: 1a).

In an EORTC-GUCG meta-analysis of tumour progression, in a subgroup of 403 patients with CIS, BCG reduced the risk of progression by 35% as compared to intravesical chemotherapy or different immunotherapy [188] (LE: 1b). The combination of BCG and MMC was not superior to BCG alone [241]. In summary, compared to chemotherapy, BCG treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression (LE: 1b).

7.2.4.4 Treatment of CIS in prostatic urethra and upper urinary tract

Patients with CIS are at high risk of extravesical involvement in the UUT and in the prostatic urethra. Solsona et al. found that 63% of 138 patients with CIS developed extravesical involvement initially or during follow-up [242]. Patients with extravesical involvement had worse survival than those with bladder CIS alone [242] (LE: 3). In the prostate, CIS might be present only in the epithelial lining of the prostatic urethra or in the prostatic ducts [37]. These situations should be distinguished from tumour invasion into the prostatic stroma (stage T4a in bladder tumours), and for which immediate radical cystoprostatectomy is mandatory. Patients with CIS in the epithelial lining of the prostatic urethra can be treated by intravesical instillation of BCG. Transurethral resection of the prostate can improve contact of BCG with the prostatic urethra [100, 243] (LE: 3). However, potential spread of CIS has to be considered; no suprapubic trocar-placed catheter should be used.

In patients with prostatic duct involvement, there are promising results of BCG, but only from small series. The data are insufficient to provide clear treatment recommendations and radical surgery should be considered [243, 244] (LE: 3). Treatment of CIS that involves the UUT is discussed in the EAU Guidelines on Urothelial Tumours of the Upper Urinary Tract [1].

7.2.4.5 Summary of evidence – treatment of carcinoma in situ

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma in situ (CIS) cannot be cured by an endoscopic procedure alone.</td>
<td>4</td>
</tr>
<tr>
<td>Compared to intravesical chemotherapy, bacillus Calmette-Guérin treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression.</td>
<td>1b</td>
</tr>
</tbody>
</table>
Flowchart 7.1: Treatment strategy in primary or recurrent tumour(s) without previous BCG*

- Consider tumour appearance and early post-operative situation

Presumably low- or intermediate-risk tumour with low previous recurrence rate (< 1 recurrence per year) and EORTC recurrence score < 5
No perforation, no extensive resection, no bleeding with clots after TURB

Single instillation of chemotherapy (Strong)

Consider completeness of the resection and pathological report

- Apparently muscle-invasive or high-risk tumour (sessile appearance etc.), frequently recurrent tumour (more than 1 recurrence per year);
- Bladder perforation, bleeding with clots

Flowchart 7.1: Treatment strategy in primary or recurrent tumour(s) without previous BCG*

Presumably low- or intermediate-risk tumour with low previous recurrence rate (< 1 recurrence per year) and EORTC recurrence score < 5
No perforation, no extensive resection, no bleeding with clots after TURB

Single instillation of chemotherapy (Strong)

Consider completeness of the resection and pathological report

Incomplete resection or no muscle (except for monofocal TaG1/LG or primary CIS) or T1

Macroscopically complete resection and Ta with muscle in the specimen or in TaG1/LG even without muscle or in primary CIS

Consider completeness of the resection and pathological report

Low-risk tumour (primary solitary TaG1/LG < 3 cm)

Intermediate-risk tumour

High-risk tumour (T1 or Ta or 3/HG or multiple and recurrent and > 3 cm TaG1-2/LG)

Cystoscopy (GR: A) at 3 mo
If negative, cystoscopy (Strong) at 12 mo. and then yearly for 5 yr. (Weak)

Positive or suspect cystoscopy during follow-up

Tiny papillary recurrence

Larger or non-papillary recurrence

Consider patients’ age, comorbidities and preferences

Office fulguration or surveillance

Follow-up: cystoscopy (Strong) Schedule: individual (Weak)

TURB + biopsies from abnormal looking mucosa (Strong), bladder random biopsies if indicated* (Strong), prostatic urethra biopsy if indicated* (Strong) (See text in guidelines)

Consider pathological report

Positive cystoscopy with no visible tumour in the bladder during follow-up

Re-check upper tract (Strong)
Bladder random biopsies (Strong), prostatic urethra biopsy in men (Strong), if available use PDD (Strong)

Consider pathological report

Non-muscle invasive recurrence

Muscle invasive recurrence

Consider previous history and pathological report (see flowchart II)

See MIBC guidelines

Tiny papillary recurrence

Larger or non-papillary recurrence

Positive or suspect cystoscopy during follow-up

No

Yes

Explain the risk and consider radical cystectomy

Intravesical BCG for 1-3 yr. (Strong)
Cystoscopy (Strong) and cytology (Strong) at 3 mo.
If negative, cystoscopy and cytology every 3 mo. for 2 yr., every 6 mo. thereafter until 5 yr. and then yearly (Weak), CT/IVU or IVU yearly (Weak)

Non-muscle invasive recurrence

Muscle invasive recurrence

For details and explanations see the text of the guidelines
BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; MIBC = muscle-invasive bladder cancer; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.
7.3 Treatment of failure of intravesical therapy

7.3.1 Failure of intravesical chemotherapy
Patients with NMIBC recurrence after a chemotherapy regimen can benefit from BCG instillations. Prior intravesical chemotherapy has no impact on the effect of BCG instillation [189] (LE: 1a).

7.3.2 Recurrence and failure after intravesical bacillus Calmette-Guérin (BCG) immunotherapy
Categories of unsuccessful treatment with intravesical BCG are presented in Table 7.2.

Table 7.2: Categories of unsuccessful treatment with intravesical BCG

<table>
<thead>
<tr>
<th>BCG failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whenever a MIBC is detected during follow-up.</td>
</tr>
<tr>
<td>BCG-refractory tumour:</td>
</tr>
<tr>
<td>1. If high-grade, non-muscle-invasive papillary tumour is present at three months [245]. Further conservative treatment with BCG is associated with increased risk of progression [165, 246] (LE: 3).</td>
</tr>
<tr>
<td>2. If CIS (without concomitant papillary tumour) is present at both three and six months. If patients with CIS present at three months, an additional BCG course can achieve a complete response in &gt; 50% of cases [37] (LE: 3).</td>
</tr>
<tr>
<td>3. If high-grade tumour appears during BCG therapy*.</td>
</tr>
<tr>
<td>High-grade recurrence after BCG. Recurrence of high-grade/grade 3 (WHO 2004/1973) tumour after completion of BCG maintenance, despite an initial response [247] (LE: 3).</td>
</tr>
<tr>
<td>BCG intolerance</td>
</tr>
<tr>
<td>Severe side effects that prevent further BCG instillation before completing treatment [222].</td>
</tr>
</tbody>
</table>

* Patients with low-grade recurrence during or after BCG treatment are not considered to be a BCG failure.

7.3.3 Treatment of BCG failure and recurrences after BCG
Treatment recommendations and options are provided in Sections 7.5 and 7.7. They reflect the categories mentioned in Table 7.2 and tumour characteristics at the time of recurrence.

Patients with BCG failure are unlikely to respond to further BCG therapy; RC is therefore the preferred option. Various studies suggest that repeat BCG therapy is appropriate for non-high-grade and even for some high-grade recurrent tumours [248, 249] (LE: 3). Additionally, there are now several bladder preservation strategies available that can be categorised as intravesical immunotherapy [250], intravesical chemotherapy, device-assisted therapy (see Section 7.2.1.3.2), and combination therapy (see Section 7.2.3) [251]. Changing from BCG to these options can yield responses in selected cases with BCG treatment failure [248, 250-258] (LE: 3).

Treatments other than RC must be considered oncologically inferior in patients with BCG failure at the present time [165, 245, 246] (LE: 3).

Little is known about the optimal treatment in patients with high-risk tumours who could not complete BCG instillations because of intolerance.

Non-high-grade recurrence after BCG is not considered as BCG failure. Treatment decision should be individualised according to tumour characteristics. It could include chemotherapy or repeat BCG instillations, but the published evidence is very low.

7.3.4 Summary of evidence - treatment failure of intravesical therapy

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior intravesical chemotherapy has no impact on the effect of bacillus Calmette-Guérin (BCG) instillation.</td>
<td>1a</td>
</tr>
<tr>
<td>Treatments other than radical cystectomy must be considered oncologically inferior in patients with BCG failure.</td>
<td>3</td>
</tr>
</tbody>
</table>
BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; HG = high-grade; IVU = intravenous urography; LG = low-grade; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.

7.4 Radical cystectomy for NMIBC

There are several reasons to consider immediate RC for selected patients with NMIBC:

- The staging accuracy for T1 tumours by TURB is low with 27-51% of patients being upstaged to muscle-invasive tumour at RC [122, 142, 259-262] (LE: 3).
- Some patients with NMIBC experience disease progression to muscle-invasive disease (Table 6.2).
- Patients who experience disease progression to muscle-invasive stage, have a worse prognosis than those who present with ‘primary’ muscle-invasive disease [263, 264].

The potential benefit of RC must be weighed against its risks, morbidity, and impact on quality of life. It is reasonable to propose immediate RC in those patients with NMIBC who are at highest risk of disease progression (see Section 7.6) [56, 120, 151, 153, 265] (LE: 3).
The benefits and risks of immediate and delayed RC should be discussed with patients, in a shared decision-making process. Individual additional prognostic factors in T1 tumours mentioned in Sections 4.7 and 6.4 should be considered. Early RC is strongly recommended in patients with BCG-refractory tumours, as mentioned above. A delay in RC may lead to decreased disease-specific survival [266] (LE: 3). In patients in whom RC is performed before progression to MIBC, the five-year disease-free survival rate exceeds 80% [267-269] (LE: 3).

### 7.5 Guidelines for adjuvant therapy in TaT1 tumours and for therapy of carcinoma in situ

<table>
<thead>
<tr>
<th>General recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Counsel smokers with confirmed non-muscle-invasive bladder cancer (NMIBC) to stop smoking.</td>
<td>Strong</td>
</tr>
<tr>
<td>The type of further therapy after transurethral resection of the bladder (TURB) should be based on the risk groups shown in Table 6.3 and Section 7.6.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients with T1 tumours presumed to be at low risk and in those presumed to be at intermediate risk with previous low recurrence rate (≤ one recurrence per year) and expected EORTC recurrence score &lt; 5, one immediate chemotherapy instillation is recommended.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients with intermediate-risk tumours (with or without immediate instillation), one-year full-dose bacillus Calmette-Guérin (BCG) treatment (induction plus three-weekly instillations at 3, 6, and 12 months), or instillations of chemotherapy (the optimal schedule is not known) for a maximum of one year is recommended. The final choice should reflect the individual patient’s risk of recurrence and progression as well as the efficacy and side effects of each treatment modality.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients with high-risk tumours, full-dose intravesical BCG for one to three years (induction plus three-weekly instillations at 3, 6, 12, 18, 24, 30, and 36 months), is indicated. The additional beneficial effect of the second and third years of maintenance should be weighed against its added costs and inconveniences.</td>
<td>Strong</td>
</tr>
<tr>
<td>Offer transurethral resection of the prostate, followed by intravesical instillation of BCG to patients with CIS in the epithelial lining of the prostatic urethra.</td>
<td>Weak</td>
</tr>
<tr>
<td>Discuss immediate radical cystectomy with patients at highest risk of tumour progression (see Section 7.6).</td>
<td>Strong</td>
</tr>
<tr>
<td>Perform a radical cystectomy (RC) to patients with BCG failure (see Section 7.7).</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients with BCG-refractory tumours, who are not candidates for RC due to comorbidities, use preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia).</td>
<td>Weak</td>
</tr>
</tbody>
</table>

### Recommendations – technical aspects for treatment

#### Intravesical chemotherapy

- If given, administer a single immediate instillation of chemotherapy within 24 hours after TURB. **Weak**
- Omit a single immediate instillation of chemotherapy in any case of overt or suspected bladder perforation or bleeding requiring bladder irrigation. **Strong**
- Give clear instructions to the nursing staff to control the free flow of the bladder catheter at the end of the immediate instillation. **Strong**
- The optimal schedule and duration of further intravesical chemotherapy instillation is not defined; however, it should not exceed one year. **Weak**
- If intravesical chemotherapy is given, it is advised to use the drug at its optimal pH and to maintain the concentration of the drug by reducing fluid intake before and during instillation. **Strong**
- The length of individual instillation should be one to two hours. **Weak**

#### BCG intravesical immunotherapy

- Absolute contraindications of BCG intravesical instillation are:
  - during the first two weeks after TURB; **Strong**
  - in patients with visible haematuria;
  - after traumatic catheterisation;
  - in patients with symptomatic urinary tract infection.
### 7.6 Treatment recommendations in TaT1 tumours and carcinoma *in situ* according to risk stratification

<table>
<thead>
<tr>
<th>Risk category</th>
<th>Definition</th>
<th>Treatment recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-risk tumours</td>
<td>Primary, solitary, TaG1 (PUNLMP, LG), &lt; 3 cm, no CIS</td>
<td>One immediate instillation of intravesical chemotherapy after TURB.</td>
</tr>
<tr>
<td>Intermediate-risk</td>
<td>All tumours not defined in the two adjacent categories (between the category of low and high risk).</td>
<td>In patients with previous low recurrence rate (less than or equal to one recurrence per year) and expected EORTC recurrence score &lt; 5, one immediate instillation of intravesical chemotherapy after TURB. In all patients either one-year full-dose BCG treatment (induction plus three-weekly instillations at three, six and twelve months), or instillations of chemotherapy (the optimal schedule is not known) for a maximum of one year.</td>
</tr>
<tr>
<td>High-risk tumours</td>
<td>Any of the following: T1 tumours; G3 (HG) tumour; CIS; Multiple, recurrent and large (&gt; 3 cm) TaG1G2/LG tumours (all features must be present).</td>
<td>Intravesical full-dose BCG instillations for one to three years or radical cystectomy (in highest-risk tumours - <em>see below</em>).</td>
</tr>
</tbody>
</table>

#### Subgroup of highest-risk tumours
- T1G3/HG associated with concurrent bladder CIS, multiple and/or large T1G3/HG and/or recurrent T1G3/HG, T1G3/HG with CIS in the prostatic urethra, some forms of variant histology of urothelial carcinoma, LVI (see Sections 4.7 and 6.4).
- BCG-refractory tumours.

Radical cystectomy should be considered.

In those who refuse or are unfit for RC intravesical full-dose BCG instillations for one to three years.

### 7.7 Treatment options for bacillus Calmette-Guérin (BCG) failure and recurrences after BCG

<table>
<thead>
<tr>
<th>Category</th>
<th>Treatment options</th>
</tr>
</thead>
</table>
| BCG-refractory tumour                 | 1. Radical cystectomy
                                       | 2. Bladder-preserving strategies in patients unsuitable for radical cystectomy |
| High-grade (HG) recurrence after BCG  | 1. Radical cystectomy
                                       | 2. Bladder-preserving strategies
                                       | 3. Repeat BCG course |
| Non-HG recurrence after BCG for primary intermediate-risk tumour | 1. Repeat BCG or intravesical chemotherapy |
|                                       | 2. Radical cystectomy |

### 8. FOLLOW-UP OF PATIENTS WITH NMIBC

As a result of the risk of recurrence and progression, patients with NMIBC need surveillance, following therapy. However, the frequency and duration of cystoscopy and imaging should reflect the individual patient’s degree of risk. Using risk tables (see Tables 6.1 and 6.2), the short- and long-term risks of recurrence and progression in individual patients may be predicted and the follow-up schedule adapted accordingly [151, 153].

When planning the follow-up schedule and methods, the following aspects should be considered:
- The prompt detection of muscle-invasive and HG/G3 non-muscle-invasive recurrence is crucial because a delay in diagnosis and therapy can be life-threatening.
• Tumour recurrence in the low-risk group is nearly always low stage and LG/G1. Small, TaLG/G1 papillary recurrence does not present an immediate danger to the patient and early detection is not essential for successful therapy [270, 271] (LE: 2b). Fulguration of small papillary recurrences on an outpatient basis could be a safe option that reduces the therapeutic burden [114] (LE: 3). Multiple authors have even suggested temporary surveillance in selected cases [272-274] (LE: 3/2a).
• The first cystoscopy after TURB at three months is an important prognostic indicator for recurrence and progression [159, 165, 275-277] (LE: 1a). Therefore, the first cystoscopy should always be performed three months after TURB in all patients with TaT1 tumours and CIS.
• In tumours at low risk, the risk of recurrence after five recurrence-free years is low [276] (LE: 3).
• Discontinuation of cystoscopy or its replacement with less-invasive methods can be considered [277].
• In tumours originally intermediate- or high risk, recurrences after ten years tumour-free are not unusual [278] (LE: 3). Therefore, life-long follow-up is recommended [277].
• The follow-up strategy must reflect the risk of extravesical recurrence (prostatic urethra in men and UUT in both genders).
• The risk of UUT recurrence increases in patients with multiple- and high-risk tumours [68] (LE: 3).
• Positive urine test results have a positive impact on the quality of follow-up cystoscopy [97] (LE: 1b) supporting the adjunctive role of urine tests during follow-up.
• In patients initially diagnosed with TaLG/G1-2 BC, US of the bladder may be a mode of surveillance in case cystoscopy is not possible or refused by the patient [279].

No non-invasive method can replace endoscopy. Follow-up is therefore based on regular cystoscopy (see Section 5.7). There is a lack of randomised studies investigating the possibility of safely reducing the frequency of follow-up cystoscopy.

As CIS is often not visible, multiple biopsies may be necessary in selected cases to confirm the efficacy of intravesical treatment in patients treated for CIS [98]. The recommendations for follow-up are mainly based on retrospective data (see Section 8.1).

8.1 Summary of evidence and guidelines for follow-up of patients after transurethral resection of the bladder for non-muscle-invasive bladder cancer

<table>
<thead>
<tr>
<th>Summary of evidence</th>
<th>LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The first cystoscopy after transurethral resection of the bladder at 3 months is an important prognostic indicator for recurrence and progression.</td>
<td>1a</td>
</tr>
<tr>
<td>The risk of upper urinary tract (UUT) recurrence increases in patients with multiple- and high-risk tumours.</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Strength rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base follow-up of TaT1 tumours and carcinoma in situ (CIS) on regular cystoscopy.</td>
<td>Strong</td>
</tr>
<tr>
<td>Patients with low-risk Ta tumours should undergo cystoscopy at three months. If negative, subsequent cystoscopy is advised nine months later, and then yearly for five years.</td>
<td>Weak</td>
</tr>
<tr>
<td>Patients with high-risk tumours should undergo cystoscopy and urinary cytology at three months. If negative, subsequent cystoscopy and cytology should be repeated every three months for a period of two years, and every six months thereafter until five years, and then yearly.</td>
<td>Weak</td>
</tr>
<tr>
<td>Patients with intermediate-risk Ta tumours should have an in-between (individualised) follow-up scheme using cystoscopy.</td>
<td>Weak</td>
</tr>
<tr>
<td>Regular (yearly) upper tract imaging (computed tomography-intravenous urography [CT-IVU] or IVU) is recommended for high-risk tumours.</td>
<td>Weak</td>
</tr>
<tr>
<td>Endoscopy under anaesthesia and bladder biopsies should be performed when office cystoscopy shows suspicious findings or if urinary cytology is positive.</td>
<td>Strong</td>
</tr>
<tr>
<td>Consider random (R)-biopsies or photodynamic diagnosis (PDD)-guided biopsies after intravesical treatment (at three or six months) in patients with CIS.</td>
<td>Weak</td>
</tr>
<tr>
<td>During follow-up in patients with positive cytology and no visible tumour in the bladder, R-biopsies or PDD-guided biopsies (if equipment is available) and investigation of extravesical locations (CT urography, prostatic urethra biopsy) are recommended.</td>
<td>Strong</td>
</tr>
<tr>
<td>In patients initially diagnosed with TaLG/G1-2 bladder cancer, use ultrasound of the bladder during surveillance in case cystoscopy is not possible or refused by the patient.</td>
<td>Weak</td>
</tr>
</tbody>
</table>
9. REFERENCES


https://www.ncbi.nlm.nih.gov/pubmed/22119022

10. CONFLICT OF INTEREST

All members of the Non-Muscle-Invasive Bladder Cancer guidelines working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/?type=panel.

This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

11. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

If a publisher and/or location is required, include:

References to individual guidelines should be structured in the following way:
Contributors’ names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.